Björn Wettermark

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi The intriguing future of pharmacoepidemiology
    Björn Wettermark
    Karolinska Institutet, Centre for Pharmacoepidemiology, Department of Medicine, Clinical Epidemiology Unit T2, Karolinska University Hospital, SE 171 76, Stockholm, Sweden
    Eur J Clin Pharmacol 69:43-51. 2013
  2. ncbi Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
    Björn Wettermark
    Karolinska Institutet, Centre for Pharmacoepidemiology, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Health Policy 94:221-9. 2010
  3. ncbi Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences
    Björn Wettermark
    Department of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Appl Health Econ Health Policy 7:137-47. 2009
  4. ncbi Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries
    Brian Godman
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Expert Rev Pharmacoecon Outcomes Res 10:199-207. 2010
  5. ncbi The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm
    Lars L Gustafsson
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Basic Clin Pharmacol Toxicol 108:224-33. 2011
  6. ncbi Forecasting drug utilization and expenditure in a metropolitan health region
    Björn Wettermark
    Department of Drug Management and Informatics, Stockholm County Council, Stockholm, Sweden
    BMC Health Serv Res 10:128. 2010
  7. ncbi Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines
    Pia Frisk
    National Corporation of Swedish Pharmacies Apoteket AB, SE 118 81, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1223-9. 2008
  8. ncbi Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe
    Björn Wettermark
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
    Pharmacoeconomics 26:537-50. 2008
  9. ncbi Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future
    Brian Godman
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Expert Rev Pharmacoecon Outcomes Res 9:475-84. 2009
  10. ncbi Adherence to guidelines for drug treatment of asthma in children: potential for improvement in Swedish primary care
    Maria Ingemansson
    Paediatric Department, Astrid Lindgrens Hospital, Karolinska University Hospital, Sweden
    Qual Prim Care 20:131-9. 2012

Detail Information

Publications15

  1. ncbi The intriguing future of pharmacoepidemiology
    Björn Wettermark
    Karolinska Institutet, Centre for Pharmacoepidemiology, Department of Medicine, Clinical Epidemiology Unit T2, Karolinska University Hospital, SE 171 76, Stockholm, Sweden
    Eur J Clin Pharmacol 69:43-51. 2013
    ..A potential threat is that the increasing amounts of data available in registries may add fuel to the debate on confidentiality. The too strict application of privacy rules might hinder the further development of pharmacoepidemiology...
  2. ncbi Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
    Björn Wettermark
    Karolinska Institutet, Centre for Pharmacoepidemiology, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Health Policy 94:221-9. 2010
    ..This resulted in reimbursement restrictions for 26 substances, e.g. all angiotensin receptor blockers (ARBs)...
  3. ncbi Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences
    Björn Wettermark
    Department of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Appl Health Econ Health Policy 7:137-47. 2009
    ..We hope this opinion paper is the first step in the process to develop and implement new demand-side initiatives building on existing 'soft regulations'...
  4. ncbi Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries
    Brian Godman
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Expert Rev Pharmacoecon Outcomes Res 10:199-207. 2010
    ....
  5. ncbi The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm
    Lars L Gustafsson
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Basic Clin Pharmacol Toxicol 108:224-33. 2011
    ....
  6. ncbi Forecasting drug utilization and expenditure in a metropolitan health region
    Björn Wettermark
    Department of Drug Management and Informatics, Stockholm County Council, Stockholm, Sweden
    BMC Health Serv Res 10:128. 2010
    ..The aim of this paper is to present the forecasting model and the predicted growth in all therapeutic areas in 2010 and 2011...
  7. ncbi Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines
    Pia Frisk
    National Corporation of Swedish Pharmacies Apoteket AB, SE 118 81, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1223-9. 2008
    ..We analysed the prescribing patterns of ARBs in Sweden by combining prescription register data with patient self-reported data...
  8. ncbi Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe
    Björn Wettermark
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
    Pharmacoeconomics 26:537-50. 2008
    ....
  9. ncbi Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future
    Brian Godman
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Expert Rev Pharmacoecon Outcomes Res 9:475-84. 2009
    ..To assess the impact of a plethora of reforms and initiatives introduced in Austria since 2002 on the actual utilization and expenditure of proton pump inhibitors and statins...
  10. ncbi Adherence to guidelines for drug treatment of asthma in children: potential for improvement in Swedish primary care
    Maria Ingemansson
    Paediatric Department, Astrid Lindgrens Hospital, Karolinska University Hospital, Sweden
    Qual Prim Care 20:131-9. 2012
    ..Adherence to guidelines in general is poor. Because asthma is the most common chronic disease in Swedish children, identifying areas for improvement regarding drug treatment for asthma is crucial...
  11. ncbi Regional variation and adherence to guidelines for drug treatment of asthma
    Marianne Heibert Arnlind
    Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 66:187-98. 2010
    ..To describe the utilization of antiasthmatic drugs in Sweden and to explore regional variations in drug utilization and adherence to guidelines for rational drug prescribing of antiasthmatics and their rationale...
  12. ncbi Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions
    Buster Mannheimer
    Karolinska Institutet, Department of Internal Medicine at Södersjukhuset, Stockholm, Sweden
    Br J Clin Pharmacol 69:411-7. 2010
    ..Dispensing data on drug combinations involving selective serotonin reuptake inhibitor (SSRI) antidepressants could help to identify areas for intensified medical education...
  13. ncbi A method to include the environmental hazard in drug prescribing
    Staffan Castensson
    Research and Development, National Corporation of Swedish Pharmacies, Apoteket AB, 118 81, Stockholm, Sweden
    Pharm World Sci 31:24-31. 2009
    ..Drug prescribing was calculated on all pharmacy sales of medicines in ambulatory care in Stockholm, Sweden (1.9 million inhabitants) during 2006...
  14. ncbi Diffusion of interferon beta in Iran and its utilization in Tehran
    Mohammad Palesh
    Division of International Health IHCAR, Department of Public Health Sciences, Karolinska Institutet, Sweden
    Pharmacoepidemiol Drug Saf 17:934-41. 2008
    ....
  15. ncbi The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months
    Björn Wettermark
    Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Pharmacoepidemiol Drug Saf 16:726-35. 2007
    ..To describe the content and potentials of the new Swedish national register on prescribed and dispensed medicines...